云顶新耀：耐赋康®被纳入《2025 KDIGO IgA肾病和IgA血管炎临床实践管理指南》 成为指南唯一推荐的IgA肾病一线对因治疗药物
EVEREST MEDEVEREST MED(HK:01952) Xin Lang Cai Jing·2025-09-19 05:50

Core Viewpoint - The company, 云顶新耀, announced that its drug, NEFECON®, has been included in the 2025 KDIGO Clinical Practice Guidelines for IgA Nephropathy and IgA Vasculitis, establishing it as the only recommended first-line treatment for IgA nephropathy patients at risk of progressive kidney function decline [1] Group 1 - NEFECON® is recommended for a 9-month treatment course for all IgA nephropathy patients with a risk of progressive kidney function decline [1] - The guidelines emphasize that a single 9-month treatment may not be sufficient for long-term benefits in reducing proteinuria and stabilizing estimated glomerular filtration rate (eGFR), indicating the need for extended treatment duration [1]